Kelun Group (China)

Recent papers from Kelun Group (China)

1. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLCNew England Journal of Medicine · 2026
2. Cell-Based Assay Development and Standardization for Antibody–Drug ConjugatesBioTech · 2026
3. Trajectories of Plasma Epstein–Barr Virus DNA and Clinical Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma Treated With PD ‐ L1 Inhibitors: A Post‐Hoc Analysis of a Multicenter, Phase II StudyHead & Neck · 2026
4. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 studyBreast Cancer Research · 2026
5. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled TrialJournal of Clinical Oncology · 2026
6. PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtypeJournal for ImmunoTherapy of Cancer · 2026
7. Magnetic-Field-Induced Surface Enrichment of Magnetic Carboxylated Carbon Nanotubes in Poly(vinylidene fluoride) Membranes for Antifouling UltrafiltrationACS Applied Polymer Materials · 2026
8. Effect of Brazing on Microstructure and Properties of Die-Cast Al–RE AlloysCorrosion and Materials Degradation · 2026
9. Ore genesis of the Gala gold deposit in the Garzê–Litang suture zone, western Sichuan Province: constraints from textures, trace elements and in-situ sulfur isotopes of pyriteOre Geology Reviews · 2026
10. Effect of Sodium Metabisulfite on Physicochemical Indexes and 16S rRNA-Based Microbial Communities of Fresh-Cut Potatoes During Chilled StorageFoods · 2026
11. A Halogen-Substituted Dicyanoisophorone Near-Infrared Fluorescent Probe for the Determination and Imaging of Copper(II)Analytical Letters · 2026
12. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialThe Lancet · 2026
13. Correction: Sun et al. Evolution Mechanism of Permeability Characteristics of Shale Reservoirs During Supercritical Fluid Fracturing and Displacement. Appl. Sci. 2025, 15, 10043Applied Sciences · 2026
14. Preclinical evaluation of 89Zr/177Lu/161Tb-labeled anti-CD228 monoclonal antibody for theranostics in skin cutaneous melanomaEuropean Journal of Pharmaceutics and Biopharmaceutics · 2026
15. An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors.Journal of Clinical Oncology · 2026
16. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).Journal of Clinical Oncology · 2026
17. Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.Journal of Clinical Oncology · 2026
18. Fire-YOLO26: an NMS-free dual-stream RGB–thermal network for real-time UAV forest fire detection in smoke-challenging conditionsFrontiers in Environmental Science · 2026
19. A Theranostic Study of ¹⁷⁷ Lu-Labeled Anti-ADAM9 Antibody for the Treatment of Triple-Negative Breast CancerBioconjugate Chemistry · 2026
20. Two taxonomically similar plant species are projected to become the key alternative wild resources to Ardisia crenata SimsBMC Plant Biology · 2026